Affiliation:
1. Shengjing Hospital of China Medical University
Abstract
Abstract
Background: Basement membrane (BM) genes are an important factor in the process of clear cell renal cell carcinoma (ccRCC). Thus, identifying BMs with prognostic values in ccRCC is critical.
Methods: The samples from TCGA were separated randomly into 2 cohorts, the training cohort, and the validation cohort. For the training cohort univariate Cox, Lasso, and multivariate Cox regression analyses were applied to identify prognostic BM genes and then construct a prognostic BM-genes’ signature. The nomogram was applied to predict prognosis at different clinicopathological stages and risk scores. GO and KEGG analyses were applied to the differentially expressed genes. Moreover, the CIBERSORT and ESTIMATE scores were calculated and compared between the high-risk cohort and the low-risk cohort.
Results: A prognostic risk model of four BM genes, including ADAMTS14, COL7A1, HSPG2, and TIMP3, was constructed. There were also significant differences in survival time between the high-risk and low-risk groups for the validation cohort and the entire cohort. The risk model was validated as a new independent prognostic factor for ccRCC by univariate and multivariate Cox regression together with clinicopathological characteristics. In addition, a nomogram showed good prediction. The model can also analyze the possibility of immune escape and response to immunotherapy in ccRCC patients. In addition, the results of a pan-cancer analysis showed that these four model genes were associated with immune-related genes in a variety of cancers.
Conclusion: The signature of four BM genes had a significant prognostic value for ccRCC. They may be promising targets for therapy, especially immune therapy.
Publisher
Research Square Platform LLC
Reference36 articles.
1. Renal cell carcinoma: a review of biology and pathophysiology;Nabi S,2018
2. Epidemiology of Renal Cell Carcinoma;Capitanio U;Eur Urol,2019
3. Influence of gene expression on survival of clear cell renal cell carcinoma;Berglund A;Cancer Med,2020
4. Chevrier, S., et al., An Immune Atlas of Clear Cell Renal Cell Carcinoma. Cell, 2017. 169(4): p. 736–749.e18.
5. Current and emerging therapies for first line treatment of metastatic clear cell renal cell carcinoma;Serzan MT;J Cancer Metastasis Treat,2021
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献